PBLS – Parabilis Medicines Inc
[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=PBLS#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
PBLS — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
1.22
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
Price
28.82
Target Price
Analyst Recom
Performance Q
Upside
N/A
Beta
Ticker: PBLS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-06-15 | PBLS | 25.01 | N/A | N/A | 0 |
| 2026-06-16 | PBLS | 26.57 | N/A | N/A | 0 |
| 2026-06-17 | PBLS | 26.06 | N/A | N/A | 0 |
| 2026-06-18 | PBLS | 25.97 | N/A | N/A | 0 |
| 2026-06-22 | PBLS | 27.49 | N/A | N/A | 0 |
| 2026-06-23 | PBLS | 27.41 | N/A | N/A | 0 |
| 2026-06-24 | PBLS | 27.38 | N/A | N/A | 0 |
| 2026-06-25 | PBLS | 26.28 | N/A | N/A | 0 |
| 2026-06-26 | PBLS | 29.01 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-06-15 | PBLS | 25.07 | - | - | - |
| 2026-06-16 | PBLS | 26.49 | - | - | - |
| 2026-06-17 | PBLS | 26.00 | - | - | - |
| 2026-06-18 | PBLS | 25.81 | - | - | - |
| 2026-06-22 | PBLS | 27.52 | - | - | - |
| 2026-06-23 | PBLS | 27.51 | - | - | - |
| 2026-06-24 | PBLS | 27.25 | - | - | - |
| 2026-06-25 | PBLS | 26.29 | - | - | - |
| 2026-06-26 | PBLS | 28.82 | - | - | - |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-06-15 | PBLS | 0 | 0 | 0 |
| 2026-06-16 | PBLS | 0 | 0 | 0 |
| 2026-06-17 | PBLS | 0 | 0 | 0 |
| 2026-06-18 | PBLS | 0 | 0 | 0 |
| 2026-06-22 | PBLS | 376.44 | 0 | 0 |
| 2026-06-23 | PBLS | 376.44 | 0 | 0 |
| 2026-06-24 | PBLS | 376.44 | 0 | 0 |
| 2026-06-25 | PBLS | 376.44 | 0 | 0 |
| 2026-06-26 | PBLS | 374.86 | 0 | 1.22 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=PBLS 589 360 ]
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
374.86
Institutional Transactions
Beta
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
8
Growth Score
Sentiment Score
81
Actual DrawDown %
16.4
Max Drawdown 5-Year %
Target Price
P/E
Forward P/E
PEG
P/S
P/B
P/Free Cash Flow
EPS
Average EPS Est. Cur. Y
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.33
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-96.8
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
[iframe https://widget.finnhub.io/widgets/recommendation?symbol=PBLS 589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=PBLS 589 450 ]
◆
PBLS
Healthcare
$28.80
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
0
Sup Dist
11.9%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
0%
EPS NY
0%
Long-Term Value
Quality companies, undervalued
WEAK
Quality
8
PBLS — P/E HistoricalBiotechnology
Parabilis Medicines, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 145
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
PBLS
Latest News
—
Caricamento notizie per PBLS…
stock quote shares PBLS – Parabilis Medicines Inc Stock Price stock today
news today PBLS – Parabilis Medicines Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PBLS – Parabilis Medicines Inc yahoo finance google finance
stock history PBLS – Parabilis Medicines Inc invest stock market
stock prices PBLS premarket after hours
ticker PBLS fair value insiders trading